Trade Names:Anturane- Capsules 200 mg- Tablets 100 mgApo-Sulfinpyrazone (Canada)
Potent uricosuric agent that inhibits renal tubular reabsorption of uric acid and reduces renal tubular secretion of other organic anions; possesses antithrombotic and platelet-inhibiting effects.
Sulfinpyrazone is well absorbed after oral administration.
98% to 99% of sulfinpyrazone is bound to plasma proteins.
Around 50% of an orally administered dose appears in urine after 24 h, 90% as unchanged drug and 10% as its active metabolite, N 1 -p-hydroxyphenol.
Treatment of chronic and intermittent gouty arthritis. Not intended for relief of acute attack of gout.
Post MI treatment (within 1 to 6 mo of acute MI) to decrease incidence of sudden cardiac death. May also be used to reduce frequency of systemic embolism in rheumatic mitral stenosis.
Active peptic ulcer or symptoms of GI inflammation or ulceration; hypersensitivity to phenylbutazone or other pyrazoles; blood dyscrasias.
PO Initial: 200 to 400 mg daily in 2 divided doses with meals or milk, gradually increasing to full maintenance dosage in 1 wk. Maintenance: 200 to 800 mg daily, given in 2 divided doses; may increase or decrease after serum urate level is controlled. In case of acute exacerbations, administer concomitant treatment with indomethacin (or another NSAID) or colchicine.
Increased hepatotoxicity and reduced efficacy of acetaminophen may occur.Anticoagulants, sulfonylureas (eg, tolbutamide)
Blood levels and toxicity of these agents may increase.Salicylates
Uricosuric action of sulfinpyrazone may be reduced.Verapamil
Reduced efficacy of verapamil may occur.
None well documented.
Nausea; vomiting; epigastric distress.
Blood dyscrasias, including anemia; leukopenia; agranulocytosis; thrombocytopenia; aplastic anemia.
Bronchoconstriction (in aspirin-sensitive patients).
Use only when clearly needed.
Safety and efficacy not established.
Periodically assess renal function.
Sulfinpyrazone use may precipitate acute gouty arthritis, urolithiasis and renal colic. Adequate fluid intake (10 to 12 eight oz glasses of fluid) and alkalinization of urine are recommended to reduce potential for renal complications.
Administer with care to these patients.
Nausea, vomiting, diarrhea, epigastric pain, ataxia, labored respiration, convulsions, coma.